Adaptin Bio
Business Services · North Carolina, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
3540 Toringdon Way Ste 200, Charlotte, N...Phone Number
(888) 609-1498Website
www.adaptinbio.comRevenue
-Stock Symbol
APTNIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Adaptin Bio
Adaptin Bio, Inc. is a biopharmaceutical company headquartered in Charlotte, North Carolina, focused on developing precision cancer therapies designed to improve drug delivery to the brain and other difficult-to-reach tissues. Its proprietary BRiTE (Brain Bispecific T Cell Engager) platform, developed by Duke University researchers, uses the immune system to target specific cells and deliver therapeutics across the blood-brain barrier. Its lead candidate, APTN-101, targets EGFRvIII-positive glioblastoma and is being evaluated in a Phase 1 clinical trial. Adaptin Bio’s shares trade on the OTCQB under the ticker APTN.Explore more
Adaptin Bio Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Adaptin Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Adaptin Bio launches new products
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Adaptin Bio recently announced quarterly report
Adaptin Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Adaptin Bio is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Adaptin Bio
Click to see if Adaptin Bio had a recent Job posting/layoffs
Check if Adaptin Bio has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Adaptin Bio has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Adaptin Bio
Find 2 more new buyers
Company Profile Activity
Activity Insights
Adaptin Bio is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Adaptin Bio is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Adaptin Bio.
Adaptin Bio News & Media
Adaptin Bio Announces Opening of Enrollment in a Phase 1 Clinical Trial Evaluating Treatment of Malignant Brain Tumors with APTN-101
APTN-101’s unique mechanism of action is designed to overcome the limitations for effective treatment of malignant brain tumors by enhancing the transport of therapies across the blood-brain barrier and selectively targeting EGFRvIII+ glioma cellsAdaptin Bio Shares (Ticker: APTN) Commence Trading on the OTCQB
CHARLOTTE, N.C., May 14, 2026 (GLOBE NEWSWIRE) -- Adaptin Bio, Inc. (OTCQB: APTN), (“Adaptin” or the “Company”), a biotechnology company developing precision cancer therapeutics enabled by targeted delivery to the brain and other difficult-to-reach tissues, today announced that its common stock has commenced trading on the OTCQB® Venture Market under the ticker symbol APTN. OTCQB trading is expected to provide greater access to U.S. investors, improve liquidity, and enhance visibility within theAdaptin Bio Shares to be Quoted on the OTCQB Under Ticker Symbol APTN
CHARLOTTE, N.C., April 06, 2026 (GLOBE NEWSWIRE) -- Adaptin Bio, Inc. (OTCQB: APTN), (“Adaptin” or the “Company”), a biotechnology company developing precision cancer therapeutics enabled by targeted delivery to the brain and other difficult-to-reach tissues, today announced that its common shares have been approved for quotation on the OTCQB® Venture Market under the ticker symbol APTN. Quotation on the OTCQB is expected to provide greater access to U.S. investors, improve liquidity, and enhancAdaptin Bio Advances Novel Brain Cancer Treatment Candidate Towards Phase 1 Glioblastoma Clinical Trial
The Preston Robert Tisch Brain Tumor Center grants first IRB approval for APTN-101’s Phase I clinical trial, enabling patient recruitment to begin
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Adaptin Bio
Sign Up For FreeTo access detailed company insights
Adaptin Bio, Inc. is a biopharmaceutical company headquartered in Charlotte, North Carolina, focused on developing precision cancer therapies designed to improve drug delivery to the brain and other difficult-to-reach tissues. Its proprietary BRiTE (Brain Bispecific T Cell Engager) platform, developed by Duke University researchers, uses the immune... Read More
